Overview

This chapter connects outcome categories, invention-to-scale timing, and finance into a conditional bottleneck model for innovative start-ups in the EU and US. A patent or early investment signals promise, but advanced growth requires commercial evidence, capital matched to timing, market reach, organisational capacity, and ecosystem connectivity. An adjusted model associates EU patenting scale-ups with approximately 1.494 additional post-filing years, while later funding diverges in the rising-superstar upper tail. The sequence is functional rather than chronological, and associations do not establish a universal lifecycle or single cause.

Learning outcomes

A patent or early investment is a signal of promise, not evidence that a start-up is ready for advanced growth.
A longer commercialisation interval can extend development, legal, hiring, and market costs before the next financing milestone.
The bottleneck sequence is functional, not chronological: firms may patent, raise, partner, acquire, or hire in different orders.

Keywords

Start-upsScale-upsBottlenecksCommercialisationCapitalEcosystems

From Invention to Investable Growth

For innovative start-ups in the EU and the US, the first three questions are now connected: what outcome a firm reaches, how quickly it turns invention into commercial evidence, and whether it can obtain the capital needed for expansion. The judgment this checkpoint supports is simple but demanding: a start-up is not ready for advanced growth merely because it has a promising technology or an early investment. It must convert those signals into a position that capital, markets, managers, and ecosystems can reinforce.

From Outcome Categories to a Bottleneck Model

The comparison began with three outcome categories. An innovative start-up has a patent or venture-capital backing; a growth-oriented start-up has raised at least USD 50 million without reaching the higher category; a rising superstar has reached a valuation of at least USD 1 billion. These distinctions are useful because they show where the distribution narrows between the EU and the US. They are not, by themselves, a complete map of how an individual company travels.

That distinction changes how the evidence should be combined. The EU has a substantial population of innovative firms, but a smaller share reaches the funding and valuation thresholds used to identify more advanced outcomes. EU rising superstars also tend to take longer to scale than US counterparts. The right inference is not that every European firm is trapped at the same point. It is that the environment appears to make the passage into advanced growth less frequent and slower on average.

The patent evidence gives the first clue about why. EU scale-ups are less likely than US peers to hold a patent, but among firms that do patent, their recorded invention stocks are comparable or higher on average. EU patenting scale-ups also take longer after first filing to reach the relevant scaling milestone. This combination separates three things that are often collapsed into one word: the capacity to invent, the choice to formalise an invention, and the ability to commercialise it rapidly.

A start-up can therefore be technically strong but commercially delayed. Its founders may have developed valuable knowledge, yet still need to decide whether formal protection is worth the cost, secure rights across relevant jurisdictions, find customers or partners, and build a product that can support expansion. If those steps take longer, the firm remains exposed to uncertainty for longer. It may have to raise more money before the market has provided enough evidence to make the next round easy.

The EU–US gap is most intelligible when these observations are treated as a bottleneck model. The broad innovative base is the starting pool. Formalisation and commercialisation determine whether knowledge becomes a credible market opportunity. Funding then has to match the scale and timing of the opportunity. A firm that reaches the next threshold has not eliminated all constraints; it has demonstrated enough progress to encounter a different and often more expensive set of them.

Published by DeepMox

FAQ

Why is the bottleneck sequence functional rather than chronological?

It is functional because firms can raise money before filing, partner before expanding, or acquire rather than build; each phase still creates a distinct conversion problem.

How can commercialisation delay affect a start-up’s financing need?

It can lengthen the period spent on development, legal work, hiring, and market preparation before a milestone attracts larger commitments; the cost depends on market conditions and runway.

What does it mean to convert resources rather than accumulate them?

It means a patent, funding round, team, or investor network becomes valuable only when the firm can combine it into products, customers, expansion, and governance.

Previous13 minEU–US Innovative Start-up Capital Cliff

Next14 minEU–US Start-up Acquisitions for Market Access

EU–US Start-up Bottleneck Model

From Invention to Investable Growth

From Outcome Categories to a Bottleneck Model

FAQ